Hong Kongese chemical industry news

Revenue +12.5% to 9,371 bln KZT; EBITDA +19.6% to 2,393 bln; net profit down to 1,072 bln; net debt cut to 375 bln; production +10%; FCF +2.8%

Triple-agonist UBT251 (GLP-1/GIP/glucagon) induced up to 9.8% weight loss, improved BP and lipids vs placebo/semaglutide. Safety consistent with triple-G class; global phase-2 and China phase-3 planned

Risvutatug rezetecan, a B7-H3–targeted ADC, showed durable responses in extensive‑stage SCLC in phase I ARTEMIS‑001; global phase III in relapsed ES‑SCLC is underway.

Expands application expertise for Beauty & Care and Food & Nutrition; offers formulation development, testing, small-batch trials and product concept support for China & Hong Kong clients.

GSK acquires ozureprubart, a potential long-acting anti-IgE therapy for food allergies, with phase IIb data expected in 2027. The deal is valued at $2.2 billion.

KMG debuts in the yuan market with Dim Sum bonds on AIX, diversifying funding and expanding its investor base. The issuance attracted high investor interest and positive analyst reviews.